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Background: Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulphadoxine-pyrimethamine
(SP) decreases adverse effects of malaria during pregnancy. Zambia implemented its IPTp-SP programme in 2003.
Emergence of SP-resistant Plasmodium falciparum threatens this strategy. The quintuple mutant haplotype
(substitutions in N51I, C59R, S108N in dhfr and A437G and K540E in dhps genes), is associated with SP treatment
failure in non-pregnant patients with malaria. This study examined efficacy of IPTp-SP and presence of the quintuple
mutant among pregnant women in Mansa, Zambia.
Methods: In Mansa, an area with high malaria transmission, HIV-negative pregnant women presenting to two
antenatal clinics for the 1st dose of IPTp-SP with asymptomatic parasitaemia were enrolled and microscopy for
parasitaemia was done weekly for five weeks. Outcomes were parasitological failure and adequate parasitological
response (no parasitaemia during follow-up). Polymerase chain reaction assays were employed to distinguish
recrudescence from reinfection, and identify molecular markers of SP resistance. Survival analysis included those
who had reinfection and incomplete follow-up (missed at least one follow-up).
Results: Of the 109 women included in the study, 58 (53%) completed all follow-up, 34 (31%) had incomplete
follow-up, and 17 (16%) were lost to follow-up after day 0. Of those who had complete follow-up, 15 (26%,
95% confidence interval [CI] [16–38]) had parasitological failure. For the 92 women included in the survival analysis,
median age was 20 years (interquartile range [IQR] 18–22), median gestational age was 22 weeks (IQR range 20–24),
and 57% were primigravid. There was no difference in time to failure in primigravid versus multigravid women. Of
the 84 women with complete haplotype data for the aforementioned loci of the dhfr and dhps genes, 53 (63%,
95% CI [50–70]) had quintuple mutants (two with an additional mutation in A581G of dhps). Among women with
complete follow-up and quintuple mutants, 22% had parasitological failure versus 0% without (p = 0.44).
Conclusions: While underpowered, this study found 26% failure rates of SP given the moderate prevalence of the
quintuple mutant haplotype. Despite the presence of resistance, SP retained some efficacy in clearing parasites in
pregnant women, and may remain a viable option for IPTp in Zambia.
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In sub-Saharan Africa, there are approximately 30 million
pregnant women at risk for malaria [1], and the prevalence
of malaria in pregnancy is estimated to be about 28% [2].
Malaria infection in pregnancy is associated with severe
maternal anaemia, placental parasitaemia, low birth weight
(LBW), and increased perinatal mortality [2]. To reduce the
risk of poor outcomes, the World Health Organization
(WHO) recommends intermittent preventive treatment of
malaria in pregnancy (IPTp), specifically with sulphadoxine-
pyrimethamine (SP). Sulphadoxine-pyrimethamine for IPTp
(IPTp-SP) is given without determining parasitaemia sta-
tus as it will either treat patients with parasites or pro-
vide a prophylactic effect to non-infected patients. At the
time of the study, WHO recommended at least two doses
of SP spaced one month apart starting in the second
trimester [3].
In Zambia, it is estimated that there are more than
200,000 pregnancies at risk for malaria each year [4].
National guidelines for IPTp-SP at the time of the study
had been implemented since 2004 and called for three
doses of SP spaced one month apart, given after quick-
ening [5]. Coverage of IPTp-SP in Zambia is among the
highest in sub-Saharan Africa with 89% of pregnant
Zambian women receiving any IPTp-SP and 70% of
women receiving at least two doses [6,7].
The efficacy of the IPTp-SP strategy is threatened by
increasing SP resistance. In Zambia, SP was first used in
the late 1990s as a second-line drug for chloroquine fail-
ures. With increasing SP resistance, in 2002 artemether-
lumefantrine became the first-line drug and SP was used
to treat malaria only in children <5 kg and pregnant
women, and for IPTp [8]. In vivo SP efficacy studies
done in Zambia among children <5 years old demon-
strated an increase in SP treatment failures from 3%
(1996) to 23% (2007) in Chipata, and from 14.5% (2003)
to 47% (2007) in Mansa [9-11].
It is unknown what level of parasite resistance to SP
would render the drug ineffective for IPTp. Sulphadoxine-
pyrimethamine resistance levels were previously moni-
tored via in vivo clinical efficacy studies in children aged
6–59 months because they have not yet fully acquired im-
munity to malaria. Translating in vivo results among sick
children to SP efficacy in asymptomatic pregnant women,
who likely have some immunity to malaria, is challenging.
Furthermore, while in vivo efficacy of SP in children is de-
fined in terms of treatment efficacy, efficacy of SP-IPTp is
demonstrated by clearing of initial parasitaemia, and pre-
vention of recurrent infections because SP-IPTp’s action is
both therapeutic and prophylactic. A meta-analysis of clin-
ical studies demonstrated that IPTp-SP efficacy is main-
tained even in areas with as high as 39% SP treatment
failure in young children [12]. In vivo IPTp-SP efficacy
studies in pregnant Zambian women are lacking. There isone published study, a randomized controlled trial of the
efficacy of 2 dose versus monthly IPTp-SP, but this study
focused on HIV-positive women and was done in 2003–
2004 before resistance was firmly entrenched [13].
The presence of P. falciparum dihydropteroate synthase
(dhps) and dihydrofolate reductase (dhfr) mutations are
associated with SP drug resistance in the parasite. The
quintuple mutant haplotype, consisting of the N51I, C59R,
S108N substitutions in dhfr and the A437G and K540E
substitutions in dhps is a marker for SP treatment failure
in non-pregnant patients [14]. Furthermore, presence of
the I164L substitution in dhfr or the A581G substitution
in dhps is associated with reduced efficacy of SP in vitro
and in vivo [15-17]. There are few published studies look-
ing at molecular markers for SP resistance in Zambia. One
study of the general community in Macha, Zambia in
2006 found the quintuple marker in 6.5% of samples, and
no I164L mutations, compared to the absence of these
markers in 2000 in the same community [18]. There have
been no published studies of the presence of these
markers in parasitaemic pregnant Zambian women.
Determining the threshold level of SP resistance, in
terms of prevalence of molecular markers that would
render the IPTp-SP strategy ineffective could be used to
predict outcomes in pregnant women receiving IPTp-SP.
Furthermore, IPTp-SP efficacy in HIV-negative pregnant
women in Zambia and the corresponding presence of SP
resistance markers in malaria parasites infecting these
women are unknown. The objectives of this study were
to determine the efficacy of IPTp-SP to clear peripheral
parasites in parasitaemic pregnant women, and assess
the presence of SP-resistance genotypes among pregnant
women in Mansa, Zambia. Mansa is in Luapula Prov-
ince, the province with the highest prevalence of parasit-
aemia in children under five years of age in the country
at 21.8% in 2008, around the time of the study [6].
Methods
The target population was pregnant women attending
antenatal clinics (ANC) between January 2010 and May
2011 at two health facilities in Mansa, Zambia. Women
who were HIV negative, presented after quickening, and
had received no prior anti-malarials including IPTp-SP
during the current pregnancy were eligible for enroll-
ment. Written informed consent was obtained from all
participants.
Upon presentation, eligible women were asked about a
history of fever, asked if they took anti-malarials within
the month before enrollment, had a physical examination,
which included axillary temperature, weight and fundal
height, and were screened with a rapid diagnostic test
(RDT) (Clearview® Malaria Combo, Orgenics Ltd, Alere
Diagnostics, Yavne, Israel) that detects histidine rich pro-
tein 2 for P. falciparum and the pan-Plasmodium antigen
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found on RDT, the patient was enrolled, a malaria smear
was done to confirm RDT findings, and blood was collected
on filter paper (FTA® Elute Cards, Whatman, Maidstone,
United Kingdom) for PCR of molecular markers. Finger-
prick blood samples were used to make thick and thin
smears, slides were stained with a 5% Giemsa solution, and
then trained laboratory technicians read thick smears for
the presence of Plasmodium parasites, and thin smears for
the quantification of intracellular parasites per microlitre
(assuming total white cell count of 8,000/microlitre) [19].
All slides were re-read for quality control at a national ref-
erence laboratory. Due to the study site being remotely lo-
cated from the reference lab, results of confirmatory blood
smear were not available on day 0. If the day 0 smear was
negative, or later found to be negative during quality con-
trol reads of the slides, the patient was excluded from the
study, so that the final sample includes only women with
peripheral parasitaemia detectable by blood slide micros-
copy on day 0.
Women received three SP tablets (500 mg sulphadoxine
and 25 mg pyrimethamine per tablet), under direct obser-
vation on day 0. To ensure drug quality, all SP used in the
study was procured from Roche Pharmaceuticals via a
supplier from the UK. Patients were instructed to return
to ANC on a weekly basis for a total of five weeks. To en-
courage follow-up, women were given the equivalent of $7
(USD) at the follow-up visits to cover travel expenses, and
a community health worker visited the homes of women
who missed their follow-up appointment to remind them
about their appointments. Each follow-up visit included an
interview for fever and recent medication history including
anti-malarials, measurement of axillary temperature, and
collection of blood for blood smears, haemoglobin meas-
urement, and filter paper for polymerase chain reaction
(PCR) to be done if the blood smear was positive. Women
found to be parasitaemic on follow-up were given
artemether-lumefantrine according to national guidelines.
For quality control, all blood smears were read by two la-
boratory technicians, and all smears were reviewed by a
senior laboratory technician at the national level who de-
termined the final result. The primary endpoint was devel-
opment of parasitaemia during the follow up period.
To distinguish between reinfection versus recrudes-
cence among those with parasitaemia during follow-up,
PCR with gel electrophoresis was performed on parasites
from day 0 and the day of failure to compare the genetic
markers for merozoite surface protein 1 (msp1), merozo-
ite surface protein 2 (msp2), and glutamate-rich protein
(glurp). The different allelic types identified for msp1
(K1, MAD 20, and RO33 types) and msp2 (FC27 and
IC/3D7) were detected with specific primers in a second
nested PCR. More details of the methods used have been
described elsewhere [20].Reinfection was defined as having completely different
alleles between parasites from day 0 and day of failure. If
any similar allele was found between the day 0 and day
of failure parasite, this was considered recrudescence.
Main outcomes were classified as follows. Presence of
any parasitaemia during follow-up was categorized as
“parasitological failure”. Parasitological failures were fur-
ther described as reinfections or recrudescences as dis-
tinguished by PCR as described above. The presence of
no parasitaemia during follow-up was called “adequate
parasitological response”. Women who were enrolled at
day 0, had at least one follow-up day, but were not
present for subsequent follow-up visits were classified as
“incomplete follow-up.” Women who did not have at
least one follow-up visit after day 0 were called “lost to
follow-up”.
Sample size and power was calculated as follows. The
expected proportion of parasitic failure in pregnant
women is unknown because of limited data. An in vivo
study in Zambian children (age <5) in 2006 showed SP
resistance, defined as treatment failure excluding reinfec-
tion (PCR adjusted), to be 33% [21]. Another study, a
comprehensive literature review, examined the propor-
tional reduction in parasitaemia in women at delivery
compared with SP resistance reported in symptomatic
children with day 14 treatment failure, and found that
the reduction was more than 60% in resistances ranging
between 3–39% [12]. Since treatment failure in chil-
dren <5 years old does not correlate well with treatment
failure in pregnant women, and based on the findings of
the literature review, it was estimated that the proportion
of parasitological failures would be much lower, around
10%. To make an estimate of parasitic failure within 5% of
the true value (precision = 0.05) with 95% confidence, and
to achieve a power of 0.80, 138 patients was the target
sample size.
Characteristics of patients and their outcomes were
described using medians and frequencies. Survival ana-
lysis was done to look at time to development of parasit-
aemia among those who had parasitological failure or
incomplete follow-up, and the log-rank test was used to
test for differences between primigravid and multigravid
women [22]. This analysis was also done for the PCR-
adjusted outcomes in which recrudescences were con-
sidered failures, while reinfections were censored. Ana-
lyses were performed in SAS software version 9.3 and all
tests were performed at the 5% level of significance [23].
The ggplot2 package in R version 3.0.1 (R foundation for
statistical computing, Vienna, Austria) was used to cre-
ate the Kaplan Meier figure [24].
All available day 0 specimens for women included in
the study underwent PCR to detect mutations on the
genes for dhps and dhfr using amplification, Sanger se-
quencing, and manual scoring of chromatographs at the
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mutations on the S108N, N51I, C59R, and I164L posi-
tions of the dhfr gene, and A437G, K540E, and A581G
positions of the dhps gene were targeted. Mixed alleles
were classified as mutant. The presence of the double,
triple, and quintuple mutants was examined. The pro-
portion of parasitological failure in women with these
mutations versus without mutations was compared with
Pearson chi-squared tests.
Ethical approval for this study was obtained from insti-
tutional review boards at both the US Centers for Dis-
ease Control and Prevention and the Tropical Diseases
Research Centre in Zambia.
Results
Of the 1,052 women screened, 208 had positive RDTs
and were found eligible, none refused participation, and
ultimately 208 were enrolled. Of those enrolled, 99
(48%) were later found to be ineligible due to a negative
(n = 87) or missing (n = 12) day 0 slide when slides were
re-read for quality control. Therefore, a total of 109
women were included in the study (see Figure 1). Of
those included in the study, only 58 (53%) completed
the study; 34 (31%) had incomplete follow-up, and 17
(16%) were lost to follow-up after day 0 (see Figure 1).
The characteristics of the 92 women (those who com-
pleted the study or had incomplete follow-up) who were
ultimately included in our analysis are summarized in
Table 1. The median age of these women was 20 years
[interquartile (IQR) range 18–22 years], with a median
gestational age (by last menstrual period) of 22 weeks
(IQR range 20–24 weeks). More than half (58%) wereFigure 1 Flow diagram of enrollment and inclusion of participants.primigravid. Most of the women had a very low parasit-
aemia; the median parasitaemia was 25 parasites/micro-
litre with an IQR range of 10–56 parasites/microlitre.
Use of other malaria control measures such as indoor
residual spraying (IRS) and use of an insecticide-treated
net (ITN) the night before enrollment, was reported by
45% and 24% of women, respectively. When the charac-
teristics of women included are compared to the 116
women who dropped out or were lost to follow-up, the
only significant difference was that women not included
were less likely to be primigravid (43%, P = 0.04).
Of the 58 who completed the study, 15 (26%, 95% con-
fidence interval [CI] [16–38]) had parasitaemic failure
during follow-up. Of those with failures, 14 had speci-
mens available for genotyping of the msp1, msp2, and
glurp genetic markers. Seven (50%) were recrudescences,
while the remaining 7 (50%) were reinfections (Table 2).
Adequate parasitic response occurred in 43 (74%, 95% CI
[62–84]). The median time to failure was 21 (range 14–
35) days. There were no patient or laboratory variables
associated with the outcome of failure on bivariate
analysis including age, being primigravid, parasitaemia >25
parasites/microlitre (the median), living in a rural area,
level of education, use of an ITN the night before, or living
in a house sprayed with IRS in the previous year.
Women who completed the study, those with incom-
plete follow-up, and those with reinfection were in-
cluded in a survival analysis with the latter two groups
censored at the last follow-up visit or the time of re-
infection. For these 92 women, the mean time to failure
was 33.6 days (standard error 0.6). There was no differ-
ence in time to failure in primigravid versus multigravid
Table 1 Characteristics of study participants (N = 92)
Characteristic n (%)
Median age (intraquartile [IQR] range) 20 years (18–22 years)
Median gestational age (IQR range) 22 weeks (20–24 weeks)




Educational level (less than 6 years
schooling)
23 (66%)
Indoor residual spraying done within
last year
36 (45%)
Slept under an insecticide treated net
last night
20 (24%)
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Figure 2). Because of the small sample size and strata,
we were unable to adjust for ITN use or IRS.
Of the 84 women who had specimens with complete
haplotypes defined as those having haplotypes for dhfr
loci 51, 59, and 108 and dhps loci 437 and 540 (includes
specimens from those lost to follow-up after day 0), 20
(24%, 95% CI [16-34]) had the triple dhfr mutant only, 7
(8%, 95% CI [4-16]) had the double dhps mutant only,
and 51 (61%, 95% CI [50–70]) had quintuple mutants.
Two (2%, 95% CI [1-8]) of the samples had mutations at
codon 581 of dhps and both of these samples also hadTable 2 Results of dhfr and dhps genotyping from all day
0 specimens that had complete genotyping available
(N = 84)
n dhfr mutations dhps mutations SP-IPTp efficacy outcome
51 59 108 437 540 581 APR* F†(R‡) U§
0 – – – – – – N/A N/A N/A
1 – – + – – – 0 0 1
1 – + + – – – 0 0 1
6 – + + + + – 2 2 (1) 2
1 + – + – – – 1 0 0
1 + – + + – – 0 0 1
1 + – + + + – 1 0 0
17 + + + – – – 11 1 5
2 + + + – + – 1 0 1
1 + + + + – – 0 1 (1) 0
51 + + + + + – 16 9 (4) 26
2 + + + + + + 2 0 0
+ = either mutant or mixed genotype.
– = wildtype.
*APR = adequate parasitological response.
†F = parasitological failure.
‡R = reinfection (Only 14/15 patients with failure had specimens available for PCR.
One patient with reinfection did not have a complete genotype available).
§U = no outcome available (lost to follow-up or missing day 0 slide).the quintuple mutation, thus for the first time, a sextu-
ple mutant was found in Zambia. There were no muta-
tions identified at codon 164 of dhfr.
Of the 58 women with outcomes available, 55 had speci-
mens available for PCR (3 specimens were lost), and 47 of
these had full haplotypes available. Among the 47 women
who had the outcomes of adequate parasitic response or
parasitaemic failure, and complete haplotypes available,
the various types dhfr and dhps mutations and corre-
sponding outcomes are noted in Table 2. Of the 14 speci-
mens with the dhfr triple mutant, 2 (14%, 95% CI [2–40%])
had a failure outcome. Of the 5 specimens with the dhps
double mutant, 2 had the outcome of failure (40%, 95% CI
[12–77]). The quintuple mutant was found in 25 speci-
mens, of which 9 (36%, 95% CI [20–55]) were failures.
There was no association between quintuple mutation and
failure in this small sample. On bivariate analysis the quin-
tuple mutation was not associated with being primigravid,
living in a rural area, level of education, use of an ITN the
night before, or living in a house sprayed with IRS in the
previous year. Surprisingly, the two specimens with the
sextuple mutant were from women who had adequate
parasitic responses on follow-up.
Discussion
There was a 26% parasitaemic failure among pregnant,
HIV-negative women receiving SP for IPTp in the context
of moderate prevalence of the highly resistant quintuple
(61%) mutant, and the appearance of the sextuple mutant
(2%) among pregnant women in this study in Mansa,
Zambia. Despite the moderate prevalence of the highly re-
sistant mutant, IPTp-SP seems to maintain some efficacy
in terms of achieving and maintaining parasite clearance
for a majority of the women in our study. While this per-
centage is higher than the 10% treatment failure threshold
that WHO recommends for changing first-line anti-
malarial policy [26], it is important to note that in the case
of IPTp-SP, SP is not being used as a first-line drug to treat
malaria, and there are no anti-malarial alternatives to SP
for IPTp. Furthermore, among those who failed, there was
an average time to failure of 21 days and for those in-
cluded in survival analysis, a median time to failure of
33.6 days. The current Zambian IPTp-SP policy recom-
mends SP doses spaced at least 4 weeks apart at every
antenatal care visit after quickening until delivery [27],
suggesting that women could receive a dose at approxi-
mately the median time between previous SP and failure.
These findings contribute to the current limited literature
on how the presence of SP resistance markers in parasites
from pregnant women translates into outcomes in terms
of recurrent parasitaemia in these same women.
The correlation between prevalence of mutations in
dhfr and dhps among parasites in pregnant women and
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Figure 2 Kaplan Meier survival estimates, stratified by gravidity and PCR corrected (mean time to failure 33.6 days).
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minimal or very high prevalences of the quintuple mu-
tant [15,25,28,29]. For example in Ghana where triple,
but no quintuple mutations have been found, an in vivo
study confirmed good efficacy of IPTp-SP [30,31]. In
Benin where prevalence of the quintuple mutation was
less than 10% prior to ITPp-SP treatment, one study
found 11% of patients had parasitological failure at
1 month of follow up [32]. The limited sample size of
this Benin study prevented reporting on significance of
the relationship between the mutated haplotypes and
outcomes of low birth weight and maternal anaemia. At
the other extreme in terms of frequency of the quintuple
mutant is Malawi where 100% penetration of the quintu-
ple haplotype has been observed in parasites from preg-
nant women [33]. A study in Malawi found that despite
the complete penetration of this haplotype, IPTp-SP still
had a dose-dependent protective effect among primi-
gravidas for a composite birth outcome of small for ges-
tational age, preterm delivery, or LBW [34]. The present
study, with 61% of isolates having quintuple mutation,
adds a much-needed data point between these extremes
of quintuple mutation prevalence. This study suggests
that SP still seems to clear parasitaemia in most preg-
nant women despite the moderately high prevalence of
resistance markers among malaria infected pregnant
women. Further supporting the likelihood of continued
IPT-SP benefit in the face of resistance, a meta-analysis
found that 3 doses versus 2 doses of IPTp-SP resulted in
better birth weight outcomes — a finding that was con-
sistent across a range of SP resistance (defined by the
presence of molecular markers). The authors postulated
that doses beyond the 2nd dose might provide somecompensation for a decrease in duration of post-treatment
prophylaxis caused by drug resistance [35].
Two studies suggested the possibility that IPTp-SP given
in areas with high SP resistance might result in worse out-
comes in terms of increased maternal parasite density and
placental inflammation [15,36]. They observed that IPTp-
SP selected for an increased fraction of parasites with mu-
tations at dhps 581 [15]. The present study did find two
isolates that harbored both the dhps A581G mutation
along with the quintuple mutant haplotype; this has never
been described in Zambia. Given that Gutman et al. have
shown some continued benefit for IPTp-SP in the setting
of high resistance, the widespread nature of SP resistance,
and lack of options for IPTp, further examination of this
issue is needed [34].
Of note, this study only looks at parasite clearance in
relation to the molecular markers, not birth outcomes
such as placental malaria and maternal anaemia. Care
must be taken in extrapolating these results to effective-
ness of IPTp-SP to prevent malaria-associated adverse
birth outcomes such as LBW and neonatal mortality.
Also, women not included in the analysis were less likely
to be primigravid than those included, and since the
benefit of IPTp-SP is most seen among primigravid
women, it is possible that observed failure rates may
have been higher among those not included.
Furthermore, this study is limited by its small sample
size and narrow geographic focus. It is interesting to see
that there were no refusals for participation in the study,
but there was a high rate of either incomplete or loss to
follow up despite monetary incentives to follow-up and
reminders from community health workers. It is possible
that participants may have agreed to participate as a
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out. Furthermore, while reasons for drop-out was not sys-
tematically collected, based on the community health
worker and study manager notes, a top reason thought to
contribute to drop out was agricultural responsibilities
elsewhere. It is common for adults to travel seasonally to
work their fields, go to the forests to collect caterpillars, or
go to fisheries. Additionally, a large contributor to loss in
sample size was the high rate of false-positive RDTs. The
possibility of false positive RDTs from remaining antige-
naemia in those recently treated should be low because
women who had taken anti-malarials the month prior to
initial presentation were excluded. The RDT and micros-
copy discrepancy could be due to low-grade parasitaemias
observed in the population of asymptomatic pregnant
women being studied in Mansa, below the detection limit
of microscopy but above the RDT detection level. PCR re-
sults of blood from women who had positive RDTs but
negative smears would have helped to further explain this
issue, but were not available. Quality controls were in
place for microscopy, but the study site was remotely lo-
cated from the reference lab, making on-site confirmation
of microscopy reads not possible. So, it is also possible that
recurrent parasitaemias, especially if low, were missed.
Conclusions
This study found a 26% parasitological failure rate for
IPTp-SP relative to the moderate 61% prevalence of the
quintuple mutant among pregnant women with asymp-
tomatic malaria parasitaemia. The threat of SP resistance
looms, and continuous resistance monitoring is needed
especially in light of the emergence of the sextuple mu-
tation, but IPTp-SP seems to retain some degree of effi-
cacy in Mansa.
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